An analysis commissioned by Washington, D.C.’s Pharmaceutical Care Management Association (PCMA) recently confirmed that no correlation exists between prices and rebates contrary to claims that drug costs are proportional to consumer rebates and discounts. Read More »
Imprimis Pharmaceuticals Inc. this month gained the rights to Klarity, a new remedy for dry eye disease (DED). Read More »
Amgen recently unveiled new data from the Kyprolis and Xgeva clinical development programs at the 16th International Myeloma Workshop in New Delhi. Read More »
A majority of the biggest patient advocacy groups in the country received drug industry funding last year, with many receiving as much as $1 million or more, a study has found. Read More »
The Academy of Managed Care Pharmacy (AMCP) recently applauded Rep. Brett Guthrie's (R-KY) Pharmaceutical Information Exchange (PIE) Act of 2017 and its efforts toward its passage. Read More »
Ingrezza (valbenazine) has been approved by the Food and Drug Administration for the treatment of tardive dyskinesia in adults. Read More »
A recent Walgreens study points to a connection between pharmacy communication and patient adherence. Read More »
CVS Health's Advanced Care Scripts has earned accreditation in Specialty Pharmacy from URAC, the leader in health care accreditation, certification and overall measurement. Read More »
Amgen's results from its Phase 3 Tower study evaluating Blincyto’s efficacy have been published in the New England Journal of Medicine. Read More »
Merck & Co. Inc. recently released the results of its Phase 3 clinical study of letermovir, a drug used to prevent clinically significant cytomegalovirus infection in CMV-seropositive adult recipients of an allogeneic hematopoietic stem cell transplant, also known as bone marrow transplant. Read More »
Sandoz, a division of Novartis, has selected six finalists for the Sandoz HACk Healthcare Access Challenge. Read More »
Biogen has entered into a licensing agreement for BMS-986168 with Bristol-Myers Squibb to initiate Phase II studies for the antibody treatment for Alzheimer’s disease and progressive supranuclear palsy. Read More »
AbbVie shared the successful results of its Phase IIb clinical trial on elagolix on patients suffering from heavy menstrual bleeding due to fibroids last week. Read More »
Tocagen Inc. recently announced that its Toca 511 & Toca FC drug received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Read More »
Shire plc recently delivered data at the American Academy of Allergy, Asthma & Immunology annual meeting on its Cuvitru drug, which treats patients with primary immunodeficiency. Read More »
Sanofi and Regeneron Pharmaceuticals Inc.'s Dupixent injection has been approved by the U.S. Food and Drug Administration (FDA) for use treating adults with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies. Read More »
The Truth Initiative and CVS Health Foundation have launched an initiative to combat tobacco use at historically black colleges and universities (HBCUs). Read More »
The voluntary recall of select lots of EpiPen Auto-Injectors and EpiPen Jr devices has been expanded. Read More »
Praising President Donald Trump’s recent executive order to redirect the previous administration’s energy regulations, a spokesman for the grassroots Americans for Prosperity (AFP) has issued a statement of support. Read More »
Sanofi and Regeneron Pharmaceuticals recently presented Phase 3 Chronos study results at the late-breaking oral abstract session of the Annual Meeting of the American Academy of Dermatology. Read More »
Alerts Sign-up
